Fda approves orphan-drug designation for jaguar health's crofelemer for treatment of diarrhea in cholera

World health organization (who) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium vibrio cholerae crofelemer previously granted orphan-drug designation by the fda and the european medicines agency (ema) for both short bowel syndrome and microvillus inclusion disease san francisco, ca / accesswire / december 17, 2024 / jaguar health (nasdaq:jagx) (jaguar) family company napo pharmaceuticals (napo) today announced that the u.s. food and drug administration (fda) has granted orphan-drug designation (odd) to crofelemer, the company's novel plant-based prescription drug, for treatment of diarrhea in cholera. "we are very pleased that crofelemer has been granted orphan-drug designation for this important indication," said steven king, phd, jaguar's chief sustainable supply, ethnobotanical research & ip officer.
JAGX Ratings Summary
JAGX Quant Ranking